TY - BOOK ID - 14305347 TI - Checkpoint controls and targets in cancer therapy PY - 2009 SN - 1607611775 9786612824708 1607611783 1282824708 PB - Totowa, N.J. ; London : Humana, DB - UniCat KW - Antineoplastic agents -- Development. KW - Cancer cells -- Growth -- Regulation. KW - Cellular control mechanisms. KW - Drug Resistance, Neoplasm KW - Cell Cycle KW - Pharmacology KW - Cell Cycle Proteins KW - Antineoplastic Agents KW - Neoplasms KW - Drug Therapy KW - Proteins KW - Biological Science Disciplines KW - Therapeutics KW - Cell Physiological Processes KW - Diseases KW - Therapeutic Uses KW - Drug Resistance KW - Amino Acids, Peptides, and Proteins KW - Pharmacologic Actions KW - Pharmacological Phenomena KW - Analytical, Diagnostic and Therapeutic Techniques and Equipment KW - Natural Science Disciplines KW - Cell Physiological Phenomena KW - Physiological Phenomena KW - Chemicals and Drugs KW - Disciplines and Occupations KW - Phenomena and Processes KW - Chemical Actions and Uses KW - Oncology KW - Public Health - General KW - Animal Biochemistry KW - Human Anatomy & Physiology KW - Public Health KW - Medicine KW - Health & Biological Sciences KW - Antineoplastic agents KW - Cancer cells KW - Development. KW - Growth KW - Regulation. KW - Cell regulation KW - Regulation of cancer cell growth KW - Medicine. KW - Cancer research. KW - Pharmacology. KW - Oncology. KW - Biomedicine. KW - Cancer Research. KW - Pharmacology/Toxicology. KW - Tumors KW - Drug effects KW - Medical pharmacology KW - Medical sciences KW - Chemicals KW - Chemotherapy KW - Drugs KW - Pharmacy KW - Cancer research KW - Clinical sciences KW - Medical profession KW - Human biology KW - Life sciences KW - Pathology KW - Physicians KW - Physiological effect KW - Biological control systems KW - Cell metabolism KW - Cellular control mechanisms UR - https://www.unicat.be/uniCat?func=search&query=sysid:14305347 AB - There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are closely associated with cancers that are highly resistant to therapeutic interventions. Checkpoint Controls and Targets in Cancer provides present-day mechanistic understandings of how multiple sets of proteins orchestrate cell cycle progression, discusses critical checkpoint controls that are evaded for cancer development, focuses on checkpoint pathways associated with antitumor effects, and identifies specific checkpoint regulators for targeting with small molecules in the clinical management of cancer. These aspects of cell cycle checkpoints are articulated critically by renowned experts from both academia and industry, and new concepts are forwarded that challenge existing dogmas. Collectively, Checkpoint Controls and Targets in Cancer provides a unique collection of insightful contributions, which are timely and offer significant interest and appeal to basic, translational and clinical scientists. ER -